OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
04 Enero 2022 - 11:00AM
OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual
Conference
Leuven,
BELGIUM, Boston,
MA, US – January
4,
2022 –
06.00
PM CET – Oxurion
NV (Euronext Brussels: OXUR), a biopharmaceutical company
developing next generation standard of care ophthalmic therapies,
with a clinical stage portfolio in vascular retinal disorders,
today announces its management will present and meet with investors
at the H.C. Wainwright BioConnect 2022 Virtual
Conference:
H.C. Wainwright BioConnect 2022
Virtual ConferenceJanuary 10-13, 2022Pre-recorded CEO Presentation
available starting on January 10 at 7:00 AM ET
For more information, please visit Oxurion’s
events
page:www.oxurion.com/news-events#view-conferences_events-page
END
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michael DillenChief Corporate
DevelopmentTel: +32 479 783583Michael.dillen@oxurion.com
|
EU MEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel:
+44 (0) 203 928 6900oxurion@medistrava.com USICR
WestwickeChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (Wet AMD) and retinal vein
occlusion (RVO).
Oxurion is aiming to build a leading global
franchise in the treatment of retinal vascular disorders based on
the successful development of its two novel therapeutics:
-
THR-687 is a highly selective pan-RGD integrin antagonist that is
initially being developed as a potential first line therapy for DME
patients. Positive topline results in a Phase 1 clinical study
assessing THR-687 as a treatment for DME were announced in 2020.
Oxurion is currently conducting a Phase 2 clinical trial
(“INTEGRAL”) evaluating THR-687 in patients with DME. THR-687 also
has the potential to deliver improved treatment outcomes for
patients with wet AMD and RVO.
-
THR-149 is a potent plasma kallikrein inhibitor being developed as
a potential new standard of care for the 40-50% of DME patients
showing suboptimal response to anti-VEGF therapy. THR-149 has shown
positive topline Phase 1 results for the treatment of DME. The
company is currently conducting a Phase 2 clinical trial
(“KALAHARI”) evaluating multiple injections of THR-149 in DME
patients previously showing a suboptimal response to anti-VEGF
therapy. Following positive data from Part A of this Phase 2 study
(dose selection), the Company has initiated Part B of the
study.
Oxurion is headquartered in Leuven, Belgium, and
is listed on the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com.
Important information about forward-looking
statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024